HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Progressive multiple cystic changes in both lungs in a patient treated with gefitinib for lung adenocarcinoma with multiple lung metastases.

Abstract
Gefitinib is regarded as a relatively safe agent for the treatment of an advanced non-small cell lung cancer (NSCLC). Pulmonary toxicity such as interstitial lung disease associated with gefitinib is uncommon with an estimated all time incidence around 1% worldwide. Moreover, a case of gefitinib associated with pulmonary cystic changes has not been reported yet. In this report we present a case of progressive multiple air cystic changes in both lungs in a patient with NSCLC and intrapulmonary metastases who underwent a gefitinib therapy.
AuthorsYon Ju Ryu, Eun Mi Chun, Soon Nam Lee, Sung Shin Shim
JournalKorean journal of radiology (Korean J Radiol) 2014 Mar-Apr Vol. 15 Issue 2 Pg. 300-4 ISSN: 2005-8330 [Electronic] Korea (South)
PMID24642811 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Quinazolines
  • Gefitinib
Topics
  • Antineoplastic Agents (adverse effects)
  • Brain Neoplasms (secondary)
  • Carcinoma, Non-Small-Cell Lung (drug therapy, secondary)
  • Cysts (chemically induced)
  • Female
  • Gefitinib
  • Humans
  • Lung (pathology)
  • Lung Diseases (chemically induced)
  • Lung Diseases, Interstitial
  • Lung Neoplasms (drug therapy)
  • Middle Aged
  • Quinazolines (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: